Novo’s Ozempic copy 15% cheaper, but Discovery still won’t change its position
Novo Nordisk’s Extensior launches in SA on 31 July at a 15% discount, but Discovery Health says it is still not enough to expand medical-scheme funding.
As it rages, the semaglutide debate exposes public trust deficit in healthcare
A Mail & Guardian opinion piece: the SA semaglutide debate is at heart a crisis of public trust in the institutions responsible for health.
Dozen weight-loss generics being reviewed for SA
SAHPRA is reviewing 12 generic semaglutide applications after Novo Nordisk’s SA patent expired, with more approvals expected to widen access.